Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Niraparib for Leiomyosarcoma With Alterations in the Homologous Recombination DNA Repair Pathway

NCT05174455 is registered in ClinicalTrials.gov with David Liebner, MD as lead sponsor.

NCT NCT05174455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05174455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Niraparib for Leiomyosarcoma With Alterations in the Homologous Recombination DNA Repair Pathway
Lead sponsor
David Liebner, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
December 1, 2023
Completion date
December 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced leiomyosarcoma, metastatic leiomyosarcoma, stage iii retroperitoneal sarcoma ajcc v8, stage iiia retroperitoneal sarcoma ajcc v8, stage iiib retroperitoneal sarcoma ajcc v8, stage iv retroperitoneal sarcoma ajcc v8, unresectable leiomyosarcoma